SCHEMBL956294

SCHEMBL956294

CCn1cc(-c2nc(-c3ccccc3)c(C(N)=O)s2)c(C)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.52
DBF4 Q9UBU7 5/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
ALDH1A1 P00352 5/20 0.45
HPGD P15428 4/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 3/20 0.42
NPC1 O15118 2/20 0.42
HSD17B10 Q99714 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 2/20 0.42
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
IKBKB O14920 1/20 0.40
RECQL P46063 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953577 0.91 CDC7 (0.50) CDC7DBF4CCNE1CDK2ALDH1A1
SCHEMBL4740819 0.75 CDC7 (0.85) CDC7DBF4CCNE1CDK2ALDH1A1
SCHEMBL952241 0.73 CDC7 (0.52) CDC7DBF4CCNE1CDK2ALDH1A1
SCHEMBL952688 0.72 COMT (0.36) CDC7DBF4ALDH1A1HPGDKDM4E
SCHEMBL6842728 0.72 KDM4E (0.37) CDC7DBF4ALDH1A1HPGDKDM4E
SCHEMBL956697 0.72 CDC7 (0.61) CDC7DBF4CCNE1CDK2ALDH1A1
SCHEMBL952078 0.72 CDC7 (0.50) CDC7DBF4CCNE1CDK2ALDH1A1
SCHEMBL12125680 0.72 COMT (0.54) ALDH1A1HPGDKDM4EMAPTHSD17B10
SCHEMBL954265 0.70 CDC7 (0.51) CDC7DBF4CCNE1CDK2ALDH1A1
SCHEMBL952124 0.70 CDK2 (0.53) CDC7DBF4CCNE1CDK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885CCNE1 1329/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885CCNE1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.